Obama Cools the Stem-Cell Debate
By Jesse Reynolds,
San Francisco Chronicle
| 04. 27. 2009
While juggling a collapsing economy and major initiatives during his first months in office, President Obama tackled - and cooled - a contentious issue that has simmered for almost 10 years: embryonic stem cell research. His March 9 executive order fulfilled a campaign promise to lift his predecessor's restrictions on its federal funding.
The president outlined his new approach, leaving the details up to the National Institutes of Health. A week ago, the NIH unveiled its draft guidelines.
The new regulations would permit federal support for research with stem cell lines derived from embryos that are created, but not used, for fertility treatments. There are hundreds of thousands of such excess embryos in storage, most scheduled for eventual destruction regardless of scientists' activities. At the same time, federal support would not be permitted for work with stem cell lines derived from embryos created with cloning techniques - if any are ever successfully produced.
This is a thoughtful approach, and the right thing to do.
There are very good reasons - technical, ethical and political - why cloning-based stem cell research...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...